Tisagenlecleucel Drug Asset Due Diligence Report 2026

This Tisagenlecleucel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

190

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tisagenlecleucel can convert its Autologous CAR-T profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tisagenlecleucel (query alias: tisagenlecleucel)
Modality / target	Autologous CAR-T; CD19; CD19 modulators, T lymphocyte replacements
Highest global status	Approved
Originator	Novartis Pharma AG
Active developers	University of Pennsylvania, Novartis Pharma AG, Novartis Pharmaceuticals Corp.

The MCP disease footprint includes Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, CD19-positive B-cell acute lymphoblastic leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT2033250787	Phase 4	募集中	30	DNA extracted from tumor tissue, bone marrow aspirate and/or blood will be tested to quantify muCAR19 transgene by qPCR to calculate VCN. muCAR19 levels will be reported as either "detectable" or as "non-detectable", in which case the level is below the limit of detection. Reports are generated for each participant, one report for VCN and one for RCL, separately. For cases where there is insufficient DNA for qPCR measurement, or when tissue contains bone that may interfere with DNA extraction, IHC will be considered. All cases where tumor tissue, bone marrow aspirate and/or blood containing malignant T cells, are positive for qPCR muCAR19 transgene and/or positive for muCAR19 will be discussed for additional analyses with careful consideration of VCN. VCN is a critical determinant for a decision to proceed with additional testing such as LISA. The percentage of malignant T-cells in the tissue/bone marrow aspirate and/or blood is also taken into consideration. VCN threshold to consider additional testing such as LISA, is a minimum of 0.1 viral copies/cell. Generally, the next step to prioritize is LISA, but the testing decision is dependent on availability (or lack thereof) of tumor and/or blood samples. These results are descriptive in nature and require a higher level of interpretation by a cross-functional internal Novartis team, usually with the treating clinician as well.
JPRN-jRCTs033250553	Phase 2	募集中	24	Complete response rate at 3 months post-tisagenlecleucel infusion in all subjects who received cRT, as determined by central review
NCT07676877	Phase 1	Not yet recruiting	18	Dose-limiting toxicities

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Tisagenlecleucel (tisa-cel) in pediatric and young adult patients with high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) and minimal residual disease (MRD) at the end of frontline consolidation (EOC).

Phase 2; n=121; evaluation: Positive. Reported fields: DFS(3-year, with censoring) = 69.0 % ( 55 - 79)

TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND MINIMAL RESIDUAL DISEASE AT THE END OF FRONTLINE CONSOLIDATION

Phase 2; n=121; evaluation: Positive. Reported fields: DFS(3-year, with censoring) = 69.0 % ( 55 - 79)

Acute adverse events associated with commercially available chimeric antigen receptor (CAR)-T cell infusions in the adult and pediatric population: a 5-year retrospective analysis

Not Applicable; n=469; evaluation: Positive. Reported fields: -; AE(grade 1) = 4.0 % ; AE(grade 1) = 7.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tisagenlecleucel addresses Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, CD19-positive B-cell acute lymphoblastic leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-09-27	Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China	Approved	US$40.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO